Gabapentin Market Research Report Information By Dosage Form (Tablet, Capsule, and Oral Solution), By Type (Generic and Branded), By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL GABAPENTIN MARKET, BY DOSAGE FORM

6.1. Overview

6.2. Tablet

6.3. Capsule

6.4. Oral Solution

7. GLOBAL GABAPENTIN MARKET, BY TYPE

7.1. Overview

7.2. Generic

7.3. Branded

8. GLOBAL GABAPENTIN MARKET, BY APPLICATION

8.1. Overview

8.2. Epilepsy

8.3. Neuropathic Pain

8.4. Restless Legs Syndrome

8.5. Others

9. GLOBAL GABAPENTIN MARKET, BY END-USE

9.1. Overview

9.2. Hospital Pharmacy

9.3. Retail Pharmacy

9.4. Online Pharmacy

10. GLOBAL GABAPENTIN MARKET, BY REGION

10.1. Overview

10.2. North America

10.2.1. U.S.

10.2.2. Canada

10.3. Europe

10.3.1. Germany

10.3.2. France

10.3.3. U.K

10.3.4. Italy

10.3.5. Spain

10.3.6. Rest of Europe

10.4. Asia-Pacific

10.4.1. China

10.4.2. India

10.4.3. Japan

10.4.4. South Korea

10.4.5. Australia

10.4.6. Rest of Asia-Pacific

10.5. Rest of the World

10.5.1. Middle East

10.5.2. Africa

10.5.3. Latin America

11. COMPETITIVE LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Global Gabapentin Market,

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Global Gabapentin Market,

11.7. Key developments and Growth Strategies

11.7.1. New Dosage Form Launch/Type Application

11.7.2. Merger & Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix

11.8.1. Sales & Operating Income, 2022

11.8.2. Major Players R&D Expenditure. 2022

12. COMPANY PROFILES

12.1. ZYDUS PHARMACEUTICALS, INC

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Dosage Forms Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Glenmark Pharmaceuticals Limited

12.2.1. Company Overview

12.2.2. Financial Overview

12.2.3. Dosage Forms Offered

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. SUN PHARMACEUTICAL INDUSTRIES LTD.

12.3.1. Company Overview

12.3.2. Financial Overview

12.3.3. Dosage Forms Offered

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Ascend Laboratories, LLC

12.4.1. Company Overview

12.4.2. Financial Overview

12.4.3. Dosage Forms Offered

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Apotex Inc.

12.5.1. Company Overview

12.5.2. Financial Overview

12.5.3. Dosage Forms Offered

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. TEVA PHARMACEUTICAL INDUSTRIES LTD.

12.6.1. Company Overview

12.6.2. Financial Overview

12.6.3. Dosage Forms Offered

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Aurobindo Pharma

12.7.1. Company Overview

12.7.2. Financial Overview

12.7.3. Dosage Forms Offered

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Amneal Pharmaceuticals LLC.

12.8.1. Company Overview

12.8.2. Financial Overview

12.8.3. Dosage Forms Offered

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Cipla USA, Inc.

12.9.1. Company Overview

12.9.2. Financial Overview

12.9.3. Dosage Forms Offered

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL GABAPENTIN MARKET, SYNOPSIS, 2018-2032

TABLE 2 GLOBAL GABAPENTIN MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)

TABLE 3 GLOBAL GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 4 GLOBAL GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 5 GLOBAL GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 6 GLOBAL GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 7 NORTH AMERICA GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 8 NORTH AMERICA GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 9 NORTH AMERICA GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 10 NORTH AMERICA GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 11 NORTH AMERICA GABAPENTIN MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 12 U.S. GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 13 U.S. GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 14 U.S. GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 15 U.S. GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 16 CANADA GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 17 CANADA GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 18 CANADA GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 19 CANADA GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 20 EUROPE GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 21 EUROPE GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 22 EUROPE GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 23 EUROPE GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 24 EUROPE GABAPENTIN MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 25 GERMANY GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 26 GERMANY GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 27 GERMANY GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 28 GERMANY GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 29 FRANCE GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 30 FRANCE GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 31 FRANCE GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 32 FRANCE GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 33 ITALY GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 34 ITALY GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 35 ITALY GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 36 ITALY GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 37 SPAIN GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 38 SPAIN GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 39 SPAIN GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 40 SPAIN GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 41 U.K GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 42 U.K GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 43 U.K GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 44 U.K GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 45 REST OF EUROPE GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 46 REST OF EUROPE GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 47 REST OF EUROPE GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 48 REST OF EUROPE GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 49 ASIA PACIFIC GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 50 ASIA PACIFIC GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 51 ASIA PACIFIC GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 52 ASIA PACIFIC GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 53 ASIA PACIFIC GABAPENTIN MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 54 JAPAN GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 55 JAPAN GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 56 JAPAN GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 57 JAPAN GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 58 CHINA GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 59 CHINA GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 60 CHINA GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 61 CHINA GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 62 INDIA GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 63 INDIA GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 64 INDIA GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 65 INDIA GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 66 AUSTRALIA GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 67 AUSTRALIA GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 68 AUSTRALIA GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 69 AUSTRALIA GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 70 SOUTH KOREA GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 71 SOUTH KOREA GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 72 SOUTH KOREA GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 73 SOUTH KOREA GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 74 REST OF ASIA-PACIFIC GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 75 REST OF ASIA-PACIFIC GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 76 REST OF ASIA-PACIFIC GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 77 REST OF ASIA-PACIFIC GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 78 REST OF WORLD GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 79 REST OF WORLD GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 80 REST OF WORLD GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 81 REST OF WORLD GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 82 REST OF WORLD GABAPENTIN MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 83 MIDDLE EAST GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 84 MIDDLE EAST GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 85 MIDDLE EAST GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 86 MIDDLE EAST GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 87 AFRICA GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 88 AFRICA GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 89 AFRICA GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 90 AFRICA GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

TABLE 91 LATIN AMERICA GABAPENTIN MARKET, BY DOSAGE FORM, 2018-2032 (USD BILLION)

TABLE 92 LATIN AMERICA GABAPENTIN MARKET, BY TYPE, 2018-2032 (USD BILLION)

TABLE 93 LATIN AMERICA GABAPENTIN MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 94 LATIN AMERICA GABAPENTIN MARKET, BY END-USE, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL GABAPENTIN MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL GABAPENTIN MARKET

FIGURE 4 GLOBAL GABAPENTIN MARKET, SHARE (%), BY DOSAGE FORM, 2022

FIGURE 5 GLOBAL GABAPENTIN MARKET, SHARE (%), BY TYPE, 2022

FIGURE 6 GLOBAL GABAPENTIN MARKET, SHARE (%), BY APPLICATION, 2022

FIGURE 7 GLOBAL GABAPENTIN MARKET, SHARE (%), BY END-USE, 2022

FIGURE 8 GLOBAL GABAPENTIN MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 NORTH AMERICA: GABAPENTIN MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 EUROPE: GABAPENTIN MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 ASIA-PACIFIC: GABAPENTIN MARKET, SHARE (%), BY REGION, 2022

FIGURE 12 REST OF THE WORLD: GABAPENTIN MARKET, SHARE (%), BY REGION, 2022

FIGURE 13 GLOBAL GABAPENTIN MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 14 ZYDUS PHARMACEUTICALS, INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 ZYDUS PHARMACEUTICALS, INC: SWOT ANALYSIS

FIGURE 16 GLENMARK PHARMACEUTICALS LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 GLENMARK PHARMACEUTICALS LIMITED: SWOT ANALYSIS

FIGURE 18 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 20 ASCEND LABORATORIES, LLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 ASCEND LABORATORIES, LLC: SWOT ANALYSIS

FIGURE 22 APOTEX INC..: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 APOTEX INC..: SWOT ANALYSIS

FIGURE 24 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 26 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 AUROBINDO PHARMA: SWOT ANALYSIS

FIGURE 28 AMNEAL PHARMACEUTICALS LLC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 AMNEAL PHARMACEUTICALS LLC.: SWOT ANALYSIS

FIGURE 30 CIPLA USA, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 CIPLA USA, INC.: SWOT ANALYSIS